Ublituximab (TG-1101)

Ublituximab (TG-1101) is a monoclonal antibody that targets a unique epitope on the B-lymphocyte CD20 antigen. Ublituximab (TG-1101) has been bioengineered to deliver enhanced clinical activity and potency. Developed for the treatment of B-cell proliferative disorders, including Non-Hodgkin's Lymphoma ("NHL") and Chronic Lymphocytic Leukemia ("CLL"), anti-CD20 antibodies target and aid in the depletion of B-lymphocytes. Anti-CD20 antibodies have also been shown to be effective in treating select autoimmune diseases such as Rheumatoid Arthritis ("RA") and Systemic Lupus Erythematosus ("SLE"), along with the neurological disorder Multiple Sclerosis ("MS"). Ublituximab is currently in Phase 3 clinical development for patients with hematologic malignancies and patients with multiple sclerosis.

Please click here to view our Publications Page.